1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...

11
extent of,but does not prevent, islet amyloid deposition in mice expressing the gene for
human islet amyloid polypeptide . Diabetes 54 :2235-2244
125. Lupi R,Del Guerra S,Marselli L,Bugliani M,Boggi U,Mosca F,Marchetti P,Del Prado
S 2004 Rosiglitazone prevents the impairment of human islet function induced by fatty
acids:evidence for a role of PPARγ 2 in the modulation of insulin secretion Am J Physiol
Endocrinol Metab 286:E560-E567.
126. Marselli L,Bambini MC,Lupi R,Del Guerra S,Boggi U,Mosca F,Del Prado
S,Marchetti P 2002 Rosiglitazone partially prevents free fatty acid-induced cytotoxicity
in human pancreatic islet cell [Abstract 494] Diabetologia 45(Suppl 2) A 161.
127. Zeender E,Maedler K,Bosco D,Berney T,Donath MY,Halban PA 2004 Pioglitazone
and sodium salicilate protect human β-cells against apoptosis and impaired function
induced by Glucose and Interleukin-1β.Diabetes 89:5059-5066.
128. Lin C-Y,Gurlo T,Haataja L,Hsueh WA,Butler PC 2004 Peroxisome proliferator –
activated receptor (PPAR-γ activation protects human islets from human islet amyloid
polypeptide –induced apoptosis [Abstract 137-OR] Diabetes 53(Suppl 2):A32.
129. Juhl CB,Hollingdal M,Porksen N,Prange A,Lönnqvist F,Smith O 2003 Influence of
rosiglitazone treatment on β-cell function in type 2 diabetes : Evidence of an increased
ability of glucose to entrain high-frequency insulin pulsatility J Clin Endocrinol Metab
88:3794-3800
130. Lebovitz HE,Dole JF,Patwardhan R,Rappaport EB,Freed MI 2001 Rosiglitazone
monotherapy is effective in patients with type 2 diabetes . J Clin Endocrinol Metab
86:280-288.
131. Wolffenbuttel BH,Gomis R,Squatrito S,Jones NP,Patwardhan RN 2000 Addition of
low-dose rosiglitazone to sulphonylurea therapy improves glycemic control in Type 2 dia-
betic patients. Diabet Med 17:40-47.
132. Einhorn D,Rendell M,Rosenzweig J,Egan JW,Mathisen AL,Schneider RL 2000
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2
diabetes : a randomized ,placebo-controlled study.The Pioglitazone 027 Study Group.Clin
Ther 22:1345-1409.
133. Jones TA,Sautter M,Van Gaal LF,Jones NP 2003 Addition of rosiglitazone to
metformin is most effective in obese,insulin-resistant patients with type 2 diabetes.
Diabetes Obes Metab 5:163-170.
134. Rosenblatt S,Miskin B,Glazer NB,Prince MJ,Robertson KE 2001 The impact of
pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2
diabetes mellitus. Coron Artery Dis 12:413-423 .